COMPANY NEWS & PRESS RELEASES

Updates on Qrono and the World of Drug Delivery

NEWS AND PRESS RELEASES

Qrono Awarded Phase II SBIR Contract from the National Cancer Institute to Advance Novel Targeted Loco-Regional Chemotherapy Delivery Platform (QARRUS)
November 11, 2016

Qrono and Inflammatory Response Research Announce Collaboration to Develop Long-Acting Therapeutics for Acute Radiation Syndrome
 
August 9, 2016

Qrono Announces Positive Preclinical Proof-Of-Concept Results Of Novel Targeted Loco-Regional Oncology Delivery Platform (QARRUS™) 
July 28, 2016

Qrono Announces Development Collaboration for Long-Acting Psychiatric Medicines
May 6, 2016

FDA funds computer simulations in bid to speed up development of long-acting generics
FIERCE DRUG DELIVERY, Varun Saxena, Dec 2015

Qrono Awarded Three-Year Contract from Food and Drug Administration to Support Availability of Generic Long-Acting Medicines
Dec 2015

Qrono Awarded Contract to Enhance the Immunogenicity of Dengue Vaccine; Program will demonstrate use of computational drug delivery technology to enhance dengue fever vaccines.
Nov 2015

Qrono Selected to Participate in the Buzz of BIO at the 2015 BIO International ConventionQrono is one of 16 companies selected to participate in the Pipelines of Promise category.
June 2015

Periodontitis: Balancing Nature’s Immune Response 
The latest Science Spotlight from the National Institute of Dental and Craniofacial Research highlights research at the University of Pittsburgh to treat periodontal disease. Recent exciting research findings demonstrate how better mathematics coupled with proven controlled-release materials can result in faster formulation designs that require less active ingredient than legacy approaches.
December 5, 2013

Qrono Featured in Emerging Drug Deliveries Report
MCD Group continuously researches and monitors emerging drug delivery technologies and has compiled a new report to profile some of the innovative developments at younger, emerging companies. Qrono is profiled as one of several startups that are “expected to gain momentum as they advance their technologies and produce significant clinical data.”
November 6, 2013

Qrono Named Pittsburgh Tech 50 Awards Finalist
August 13, 2013

Qrono Receives Dept. of Defense Award to Help Protect Warfighters from Toxic Nerve Agents
July 16, 2013

Qrono Featured in Pittsburgh Business Times Article
July 5, 2013

Qrono Receives National Institutes of Health Award to Improve
Treatment of Wet Age-Related Macular Degeneration

June 5, 2013

About Qrono:

Qrono reformulates FDA approved drugs and creates new, long-acting injectable (LAI) medications with improved clinical and economic benefits. Our product pipeline focuses on therapeutic areas where LAIs offer high therapeutic and economic value, such as addressing high non-adherence or solving specific drug delivery challenges. Using our computational drug delivery technology, we can design LAIs much faster than legacy practice and with reduced regulatory and technical risk.

For further information, please contact:

Larry Zana
CEO
Qrono Inc.
4551 Forbes Ave., Ste. 301 Pittsburgh, PA 15213
Phone: 412-213-8788
Email: lzana@qrono.com Internet: http://www.qrono.com

Contact Us

Send us an email and we'll get back to you ASAP! Thanks